Encapsulation, stability, and in vitro release characteristics of liposomal formulations of stavudine (D4T)

Drug Delivery: Journal of Delivery and Targeting of Therapeutic Agents

Volumn 6, Issue 1, 1999, Pages 31-37

  Katragadda, Arun K ^a   Singh, Mandip ^b   Betageri, Guru V ^a,c  

^a AUBURN UNIVERSITY   (United States)

^b FLORIDA A AND M UNIVERSITY   (United States)

^c WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

Author keywords

Encapsulation; Liposomes; Release; Stability; Stavudine

Indexed keywords

CHOLESTEROL; LIPOSOME; STAVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; DIALYSIS MEMBRANE; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG RELEASE; DRUG STABILITY; ENCAPSULATION; LIPID BILAYER; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL;

EID: 0033063380     PISSN: 10717544     EISSN: None     Source Type: Journal    
DOI: 10.1080/107175499267138     Document Type: Article

References (20)

1. Baba, M., Pauwels, R., Herdewijn, P., Desmyter, J., and Vandeputte, M. 1987. Both 2′,3′-dideoxythymidine and its 2′,3′ unsaturated derivative (2′,3′-dideoxythymidinene) are potent and selective inhibitors of human immunodeficiency virus in vitro. Biochem. Biophys. Res. Commun. 142:128-134.
2. Benita, S., Poly, P. A., Puisieux, F., and Delattre, J. 1984. Radio-opaque liposomes: Effect of formulation conditions on encapsulation efficiency. J. Pharm. Sci. 73:1751-1754.
3. Betageri, G. V. 1993. Liposomal encapsulation and stability of dideoxyinosine triphosphate. Drug Dev. Ind. Pharm. 19:531-539.
4. D'Silva, J. B., and Notari, R. E. 1982. Drug stability in liposomal suspensions: Hydrolysis of indomethacin, cyclocytidine, and p-nitrophenylacetate. J. Pharm. Sci. 71:1394-1398.
5. El-Gazayerly, O. N., and Hikal, A. H. 1997. Preparation and evaluation of acetazolamide liposomes as an ocular delivery system. Int. J. Pharm. 158:121-127.
6. Elorza, B., Elorza, M., Sainz, M., and Chantres, J. 1993. Comparison of particle size and encapsulation parameters of three liposome preparations. J. Microencapsulation 10:237-248.
7. Ganapathi, R., Krishnan, A., Woodinsky, I., Zubord, C. G., and Lesko, L. J. 1980. Effect of cholesterol content on antitumor activity and toxicity of liposome encapsulated 1-O-D arabinosylcytosine in vivo. Cancer Res. 40:630-633.
8. Kulkarni, S. B., Dipali, S. R., and Betageri, G. V. 1995. Protamine induced aggregation of unilamellar liposomes. Pharm. Sci. 1:359-362.
9. Lopez-Berestein, G., McQueen, T., and Mehta, K. 1985. Protective effect of liposomal amphotericin B against C. albicans infection. Cancer Drug Del. 2:183-189.
10. Mayer, L., Tai, L., and Bally, M. 1990. Characterization of liposomal systems containing doxorubicin. Biochim. Biophys. Acta. 1025:143-148.
11. Petersen, E. A., Ramirez-Ronda, C. H., Hardy, W. D., Sacks, H. S., Follansbee, S., Peterson, D. M., Cross, A., Anderson, R. E., and Dunkle, L. M. 1995. Dose related activity of stavudine in patients infected with human immunodeficiency virus. J. Infect. Dis. 171:S131-S139.
12. Phillips, N. C., Skamene, E., and Tsoukas, C. 1991. Liposomal encapsulation of 3′-azido 3′-deoxythymidine (AZT) results in decreased bone marrow toxicity and enhanced activity against murine AIDS induced immunosuppression. J. Acquired Immune Defic. Syndrome 4:959-966.
13. Phillips, N. C., and Tsoukas, C. 1992. Liposomal encapsulation of azidothymidine results in decreased hematopoietic toxicity and enhanced activity against murine acquired immunodeficiency syndrome. Blood 79:1137-1143.
14. Puisieux, F., and Benita, S. 1982. Towards a new galenic dosage form, the liposomes? Biomedicine 36:4-13.
15. Ryan, P. J., Davis, M. A., and Melcior, D. L. 1993. The preparation and characterization of liposomes containing X-ray contrast agents. Biochim. Biophys. Acta. 756:106-110.
16. Senior, J., and Gregoriadis, G. 1982. Stability of small unilamellar liposomes in serum and clearance from the circulation: The effect of cholesterol and phospholipid components. Life Sci. 30:2123-2136.
17. Skowron, G. 1995. Biologic effects and safety of stavudine: Overview of phase I and II clinical trials. J. Infect. Dis. 171:S113-S117.
18. Szoka, F. R., and Papahadjopoulos, D. 1978. Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse phase evaporation. Proc. Natl. Acad. Sci. USA 75:494-498.
19. Weiner, N., Martin, F., and Riaz, M. 1989. Liposomes as drug delivery system. Drug Dev. Ind. Pharm. 15:1523-1554.
20. Zeng, S., Hu, C., Wei, H., Lu, Y., Zhang, Y., Yang, J., Yun, G., Zou, W., and Song, B. 1993. Intravitreal pharmacokinetics of liposome encapsulated amikacin in a rabbit model. Ophthalmology 100:1640-1644.